Daiichi Sankyo sends US QA director to rescue Ranbaxy India ops; FDA urged to mandate closer vaccine scrutiny;

> Japan's Daiichi Sankyo has named U.S. QA director Dale Adkisson to oversee the quality and manufacturing efforts at Ranbaxy Labs in India, one of the FDA's GMP violation poster children. Article

> Following the rotavirus contamination, the FDA is being urged to require checks for barely detectable biological matter in vaccine-making. Article

> Anika Therapeutics says the FDA has OK'd corrective actions following a 2008 GMP warning letter. Article

> Boehringer Ingelheim has chosen Kuehne + Nagel to management temperature-controlled transportation in the Czech Republic, Poland, Hungary, Greece and Croatia. Release

> Simcere Pharmaceutical's Jiangsu Yanshen Biological has been fined $3.74 million by the Changzhou Food and Drug Administration for production of substandard human rabies vaccine, plus $3.36 million to cover the cost of patient re-vaccinations. Release

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.